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Cognitive symptoms are core features of mental disorders but procognitive treatments
are limited. We have proposed a “discoordination” hypothesis that cognitive impairment
results from aberrant coordination of neural activity. We reported that neonatal ventral
hippocampus lesion (NVHL) rats, an established neurodevelopmental model of schizophre-
nia, have abnormal neural synchrony and cognitive deficits in the active place avoidance
task. During stillness, we observed that cortical local field potentials sometimes resem-
bled epileptiform spike-wave discharges with higher prevalence in NVHL rats, indicating
abnormal neural synchrony due perhaps to imbalanced excitation–inhibition coupling. Here,
within the context of the hypothesis, we investigated whether attenuating abnormal neural
synchrony will improve cognition in NVHL rats. We report that: (1) inter-hippocampal syn-
chrony in the theta and beta bands is correlated with active place avoidance performance;
(2) the anticonvulsant ethosuximide attenuated the abnormal spike-wave activity, improved
cognitive control, and reduced hyperlocomotion; (3) ethosuximide not only normalized the
task-associated theta and beta synchrony between the two hippocampi but also increased
synchrony between the medial prefrontal cortex and hippocampus above control levels; (4)
the antipsychotic olanzapine was less effective at improving cognitive control and normaliz-
ing place avoidance-related inter-hippocampal neural synchrony, although it reduced hyper-
activity; and (5) olanzapine caused an abnormal pattern of frequency-independent increases
in neural synchrony, in both NVHL and control rats. These data suggest that normalizing
aberrant neural synchrony can be beneficial and that drugs targeting the pathophysiology
of abnormally coordinated neural activities may be a promising theoretical framework and
strategy for developing treatments that improve cognition in neurodevelopmental disorders
such as schizophrenia.
Keywords: neural synchrony, oscillations, schizophrenia, neurodevelopmental models, hippocampus, local field
potentials, cognitive control, spike-wave discharge
INTRODUCTION
Cognitive impairment is a core feature of schizophrenia but treat-
ments to improve cognition are limited, in part because the physi-
ological mechanisms of cognitive dysfunction are unclear. Recent
interest has been directed toward understanding the abnormal
synchrony of neural oscillations as a pathophysiological mecha-
nism that underlies the cognitive impairments in schizophrenia
(1–4). Dysfunctional neural synchrony in a wide range of fre-
quencies, including the delta (5), theta (6), beta (7), and gamma
ranges (8, 9), have been characterized in patients with schizophre-
nia. In animal models, disruption of long-range hippocampal–
prefrontal synchrony has been reported while performing a work-
ing memory task in a genetic mouse model of schizophrenia (10)
and during an open-field task in the maternal immune activa-
tion (MIA) neurodevelopmental model of schizophrenia (11).
Abnormal hippocampal–prefrontal synchrony was also observed
in the neonatal ventral hippocampus lesion (NVHL) neurode-
velopmental model but this synchrony abnormality was not itself
associated with cognitive impairment (12). In fact, aberrant neural
synchrony may be a common pathophysiology responsible for
impaired cognition in a variety of disorders (2, 13). Indeed,
treatments that normalize neural network dysfunction without
addressing the underlying cellular pathology have been sufficient
to improve cognitive function in animal models of neurodegenera-
tive diseases (14, 15). Such studies demonstrate it may be a feasible
strategy to improve cognitive functional outcomes by normalizing
aberrant neural network synchrony in cases where the network
dysfunction is part of the causal chain from the disease etiology to
the manifest cognitive symptoms.
We previously reported that NVHL rats, an established neu-
rodevelopmental animal model of schizophrenia (16), have a
cognitive control impairment that was associated with abnormal
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synchrony between the two hippocampi (12). We also detected
hippocampal–prefrontal synchrony abnormalities in these rats
during home-cage resting behaviors, but these abnormalities were
absent during place avoidance training, and so not related to
performance on the cognitive test. Clinically, the presence of hip-
pocampal dysfunction is apparent in schizophrenia. Postmortem
and neuroimaging studies indicate that the hippocampus is one
of the brain regions most consistently altered in schizophrenia
(17–22). Furthermore, functional magnetic resonance imaging
studies show dysfunctional hippocampal activities are associ-
ated with poor cognitive performance in schizophrenia patients
(23–25). Perhaps similar to the findings in NVHL rats, reduced
inter-hippocampal functional coupling has also been observed
between the left- and right-hippocampus areas in healthy carri-
ers of the CACNA1C risk variant in bipolar disorder (26), but to
our knowledge these measurements have not been carried out in
schizophrenia subjects. Because neuroimaging studies do not have
sufficient temporal resolution to detect functional synchrony at the
100-ms or faster timescales of the electrophysiological synchrony
that underlies information processing between neural networks, it
is unclear whether or not the inter-hippocampal abnormalities in
NVHL rats mimics abnormalities in schizophrenia. Regardless, it is
our opinion that animal models used to study schizophrenia do not
sensibly mimic disease features, instead they are better thought of
as being models for testing hypotheses that are relevant to under-
standing schizophrenia. Thus, we hypothesized that the abnormal
hippocampal synchrony plays a role in the pathophysiology of
cognitive control impairment in a schizophrenia-related neurode-
velopmental animal model. As outlined below, in the present
study, we tested the idea that attenuating this pathophysiology
can improve cognition.
We, like others, have proposed the discoordination hypoth-
esis, which asserts that cognitive impairment arises because of
aberrant coordination of what may otherwise be normal neural
activities (12, 27). The discoordination hypothesis is rooted in the
idea that disrupted physiological coordination and synchroniza-
tion of unitary neural processes impair the ability to selectively
and dynamically activate and suppress information for organizing
knowledge and perception into useable representations (1, 2, 27,
28). We use the term (dis)coordination to refer to the collective
temporal organization of unitary neural activity such as action and
synaptic and local field potentials (LFPs) at individual sites. Thus,
(dis)coordination can be measured at different temporal and spa-
tial scales. In the present work, we examined inter-hippocampal
synchrony of LFP oscillations. These oscillations are an exam-
ple of a long-range spatial scale neural interaction that involves
an approximate order of 105 neurons. These oscillations result
from the multiple timescales of excitation–inhibition neural activ-
ity cycles that govern spiking within these networks (29). The
discoordination hypothesis predicts that in the NVHL model,
restoring the abnormal neural synchrony to normal will attenuate
the cognitive control deficit. Accordingly, we took advantage of the
hippocampal synchrony abnormality in NVHL rats, specifically
the inter-hippocampal synchrony that was associated with cogni-
tive performance, to evaluate the prediction. We examined whether
normalizing the abnormal synchrony can attenuate the cognitive
control deficit in the NVHL rats. We observed that hippocampal
and neocortical LFPs in the NVHL rats sometimes resembled
spike-wave discharges (SWDs), a sign of network hyperexcitability.
We hypothesized that these aberrant neural activities arise from
an excitation–inhibition imbalance that may underlie abnormal
neural synchrony in the NVHL rats. Since SWD in epilepsy patients
is treated with ethosuximide (2-ethyl-2-methylsuccinimide), an
anticonvulsant that acts by blocking T-type Ca2+ channels, we
studied whether ethosuximide would attenuate the abnormal
SWD-like synchrony as well as impaired cognitive behavior and
the associated neural synchrony that we have previously described
in the NVHL model (12). We stress that our goal is to test the pre-
diction of the discoordination hypothesis, not to suggest the use of
ethosuximide as an antipsychotic. For comparison, we also exam-
ined the effects of the atypical antipsychotic olanzapine on neural
synchrony and cognitive abnormalities in NVHL rats. Given that
antipsychotics are not known to improve cognitive symptoms,
the hypothesis predicts that olanzapine will not correct either the
neural synchrony or cognitive abnormalities in NVHL rats.
We report that in NVHL rats, ethosuximide treatment atten-
uated the abnormal spike-wave activity, and most importantly,
ethosuximide normalized the cognition-associated synchrony of
theta and beta oscillations between the two hippocampi, and
improved cognitive control in the place avoidance task. Olan-
zapine was less effective at reducing the abnormal spike-wave
activity and normalizing the synchrony of oscillations between
the two hippocampi and it did not improve cognitive control in
NVHL rats, although it attenuated hyperlocomotion during the
cognitive testing. These data are consistent with the discoordi-
nation hypothesis, and support the idea that drugs targeting the
abnormal neural synchrony may be sufficient to rescue the cogni-
tive deficits in schizophrenia-related neurodevelopmental animal
models.
MATERIALS AND METHODS
All procedures were in compliance with National Institutes of
Health guidelines and were approved by Downstate Medical
Center’s Institutional Animal Care and Use Committee.
NEONATAL VENTRAL HIPPOCAMPAL LESION
The procedure followed the manual provided by Lipska and Wein-
berger. We used the exact protocol that is published in our prior
work (12). Briefly, timed-pregnant (13 or 14 days in gestation)
female Long-Evans rats were obtained from Charles River Labora-
tories (Wilmington, MA, USA). Pups were born at the Downstate
animal facility. On postnatal day 7 (P7), male pups were anes-
thetized by hypothermia. Bilateral puncture holes (relative to
bregma AP: −3.0 mm, ML: ±3.5 mm) were made in the skull
with a 30-Ga injection needle. A bilateral infusion (0.3µl/side)
of ibotenic acid solution (10µg/µl) was delivered to each ven-
tral hippocampus (relative to the skull surface DV: −5.0 mm).
Control animals were treated identically except saline was injected
instead of ibotenic acid. A subset of the NVHL and control rats
were given drug treatments as described below. The behavioral
and neural synchrony measurements from these rats were com-
pared to untreated NVHL and control rats, the data from which
were reported previously (12), although all data collection was
concurrent amongst the different treatment groups.
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DRUGS
Ibotenic acid, purchased from Sigma (St. Louis, MO, USA), was
dissolved in artificial cerebrospinal fluid (ACSF) to a final concen-
tration of 10µg/µl, pH 7.6. Ethosuximide, purchased from Sigma
(St. Louis, MO, USA), was dissolved in sterile 0.9% NaCl and a con-
centration of 100 mg/kg was injected i.p. Olanzapine, purchased
from Toronto Research Chemicals Inc. (Toronto, ON, Canada),
was dissolved in dimethyl sulfoxide (DMSO) and 1 mg/kg was
injected i.p. Both ethosuximide and olanzapine were administered
just prior to the start of behavioral training (see below) and based
on published work, they were expected to have been bioactive for
several hours, beyond the duration of behavioral training.
TWO-FRAME AVOIDANCE TASK
Five adult rats (P65) per group were trained on the two-frame
task. The rat was placed on a circular 82 cm diameter, stainless steel
rotating arena (Bio-Signal Group Corp., Brooklyn, NY, USA). The
rat’s position was tracked using an overhead camera and software
(Tracker, Bio-Signal Group Corp., Brooklyn, NY,USA). All animals
were habituated to the rotating arena the day before the start of
active place avoidance training during two 10-min sessions with-
out any shocks. On the following training trials, whenever the rat
on the rotating arena entered a 60° shock zone that was defined
in room coordinates, a mild constant current (60 Hz, <0.4 mA,
500 ms) foot shock was delivered. Foot shock was repeated every
1.5 s until the rat left the shock zone. Each place avoidance trial
was 10 min and the interval between the trials was at least 10 min.
A total of eight training trials were given on the training day. The
drugs were injected i.p. just prior to the first avoidance training
trial. Avoidance was measured by counting the number of times
the rat entered the shock zone.
LOCAL FIELD POTENTIAL AND ELECTROENCEPHALOGRAM
RECORDINGS
All rats were housed individually, exposed to a 12-h light/dark
circadian cycle, and had ad libitum access to water and food.
When rats were P55-57, electrodes were surgically implanted bilat-
erally. Rats were given post-operative Ketofen (5 mg/kg) for 2 days
after surgery and allowed to recover from the surgical procedure
for 7 days. LFPs in the dorsal hippocampus (AP: −4 mm; ML:
±2.5 mm; DV: 3 mm) and in the medial prefrontal cortex (mPFC;
AP:+3 mm; ML:±1 mm; DV: 4 mm) were recorded by implanting
75-µm Nichrome wires that were attached to a Millmax connector.
The epidural cortical electroencephalogram (EEG) was recorded
with a screw electrode in the frontal and parietal bones of each
hemisphere. All electrodes were referred to an electrode implanted
in the cerebellar white matter (AP: −10 mm; ML: +2 mm; DV:
3 mm), which seemed to be normal in NVHL rats. Recordings were
made with a wireless digital telemetry system (Bio-Signal Group,
Brooklyn, NY, USA). Recordings were made while the rats were
performing the two-frame avoidance task and in the home-cage
(for 2–3 h) during the light cycle.
The signals at the electrode connector were amplified (300
times), low-pass filtered (6 kHz) and digitized (24-bits, 12 kHz
using delta-sigma analog-digital convertors). The digital signals
were transmitted wirelessly to a recording system (dacqUSB,
Axona Ltd., St. Albans, UK) for band-pass filtering (1–500 Hz),
digital amplification and down-sampling (16-bits, 2000 Hz) using
digital signal processors. The digital electrophysiological data were
stored on computer hard drives for off-line analysis. The channels
were marked if they had saturated signals and were excluded from
further analysis if the proportion was substantial. At the end of
training and recording, the rats were trans-cardially perfused and
the brains removed for histological verification of the electrode
locations.
POWER SPECTRA
Power spectra measure the amplitude of frequency-specific oscil-
lations that arise when spatially patterned synaptic potentials
are coincident in time. These oscillations are locally generated
phenomena. As such, an oscillation itself may not be a strong indi-
cation of neural synchrony as it relates to the concept of neural
coordination (1, 27). Instead, power spectra are an estimate of
the amount and magnitude of patterns of oscillation-generating
synaptic potentials that are the fundamental components of neural
coordinating processes. The patterns of synaptic potentials must
themselves be temporally and spatially coordinated within and
between neural networks to mediate the neural computations and
information processing upon which cognition is based (29).
To compute power spectra, LFP signals were first normalized
by dividing the signal by its RMS value. This step minimized
electrode-specific signal properties caused by variability in elec-
trode location or impedance. The signal was processed using 5 s
long non-overlapping windows. For each window power spectral
density (PSD) was computed using the “pwelch” Matlab func-
tion. The spectral peak at 60 Hz was removed and the PSD was
interpolated between 58 and 62 Hz. The resulting PSD was nor-
malized by dividing it by its sum so the total power was equal
to 1. Based on the spectral profile, we then defined bands of
interest for frequency-specific phase-locking analysis. We excluded
the delta band (0–3 Hz) because of its attenuation by the hard-
ware DC-removal filter (Figure 1). We defined the theta band as
5–15 Hz, beta as 20–30 Hz in order to exclude the strong second
theta harmonic (Figure 1), slow gamma 30–55 Hz and fast gamma
as 65–100 Hz (excluding the 60-Hz region). Figure 1 shows that
the left and right hippocampal spectra are similar, as expected, and
that the spectra are attenuated in NVHL rats. Both ethosuximide
and olanzapine only caused a marginal increase in the broad-
band spectral power. This confirmation of stable spectral power
provides the starting point for the present study, which focuses
on measuring how these component oscillations are coordinated
between brain regions.
PHASE-LOCKING VALUE
The coordination of neural signals at a pair of electrodes was esti-
mated by computing the phase-locking value (PLV). Eight LFP
channel pairs were selected for PLV analysis. They were the left-
and right-hippocampi; left- and right-mPFC; left-hippocampus
and left-mPFC; right-hippocampus and right-mPFC, as well as
the inter-hemispheric and associational epidural electrode pairs.
The PLV at a pair of electrodes was computed using custom soft-
ware written in Matlab, based on a published algorithm (31). The
phase of a signal at time t and sample n φ(t, n) was obtained by
filtering the signal with a narrow-band finite input response (FIR)
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FIGURE 1 | Hippocampal power spectra. (A) Power spectra density plot
for untreated groups averaged across all subjects for NVHL (thick line) and
control (thin line) computed independently for left (opaque line) and right
(semi-transparent line) hippocampi. (B) Power spectral density plot for
Ethosuximide-treated animals. (C) Power spectra density plot for
Olanzapine-treated animals. The similarities between the corresponding left
and right spectra is a common observation, is independent of phase
synchrony, and is only indirectly related to neural coordination in that neural
oscillations are the fundamental, unitary components of neural coordination
processes such as phase synchrony and cross-frequency coupling (30).
filter using a zero phase-shift filtering algorithm followed by the
Hilbert Transform. The filters were designed using the Matlab filter
design toolbox. Filters in the range 0–100 Hz had fixed bandwidth
of 5 Hz. For bands of interest extending over several 5 Hz bands
the PLV across all such bands were averaged. Given a pair of LFP
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where θ(t, n) is the phase differenceφ1(t, n)−φ2(t, n) between the
two signals at time t sample n; N is the total number of samples;
and i is the imaginary unit. Prior work showed that the intracranial
electrode-pair specific PLVs at the four (theta, beta, slow gamma,
fast gamma) frequency bands were different between NVHL and
control rats (12). We made these comparisons between the NVHL
and control treatment groups to determine if the drug treatment
normalized neural synchrony between the particular electrode
pairs. In addition, the PLVs for the full set of electrode pairs were
studied to look for neural synchrony patterns that distinguished
the NVHL and control and the drug-treatment groups. The set
of electrode-pair and frequency-specific PLVs for each recording
session was treated as a vector with dimension 32 (8 electrode
pairs× 4 bands). Principal component analysis (PCA) was per-
formed to reduce the dimensionality and identify the most useful
measures of synchrony. Each session vector of PLVs (eight sessions
per rat) was plot in the coordinate system of the first three principal
components to visualize the group patterns. The first six principal
components explained over 90% of the variance and so for quan-
tification we only considered the first six principal components.
We quantified the distance between the vectors in each session
group by computing the 6-D Euclidean distance between all pairs
of data points within a treatment group, and also between all pairs
of data points against a reference treatment group. The untreated
control and untrained NVHL groups as well as the ethosuximide-
treated NVHL and the olanzapine-NVHL groups each served as
reference groups for the comparisons. These pair-wise group dis-
tances were compared by two-sample Student’s t -tests that were
adjusted for multiple comparisons using the Bonferroni method.
AUTOMATIC DETECTION OF SPIKE-WAVE ACTIVITY
We used an algorithm to identify activity that resembled epilepti-
form SWDs, but are observed in normal Long-Evans rats without
seizures (32). Each channel was first examined for signal satura-
tion and only data segments with brief (<50 ms) saturations were
considered for further analysis. Brief saturations in the LFP were
allowed so spike-wave complexes with a large spike component
were not removed from the analysis. We manually marked epochs
of spike-wave events using the EEGLAB toolbox for Matlab. These
epochs were used to calculate and optimize the detection parame-
ters for the automatic classifier of spike-wave events. The classifier
is a modified version of a published algorithm (33).
The algorithm worked in several steps (Figure 2):
(1) Local field potential signals (Figure 2A) were transformed
(Figure 2B) using the continuous wavelet transform (CWT)
from the Wavelet Toolbox in Matlab (Morlet wavelets, scales
5–50 with step of 5 corresponding to pseudo-frequencies
16–160 Hz).
(2) The sliding variance (50 ms long window) was computed for
each scale and all variances were summed across all scales
resulting in a single variance profile over time.
(3) Candidate spike-wave events were marked as threshold cross-
ings (red line in Figure 2C) of the summed variance series.
(4) Gaps between individual marked segments shorter than 0.75 s
were filled to create longer segments.
(5) After filling the gaps, all marked segments that were shorter
than 1 s were removed from further analysis.
(6) Each marked segment was tested for periodic spiking activ-
ity by detecting local maxima (red dots in Figure 2C) in the
summed variance signal with 50 ms smoothing applied. The
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FIGURE 2 | Spike-wave activities in NVHL and control rats.
(A) A segment of the cortical EEG with spike-wave activity. An automatic
classifier was used to detect these events. (B) The first step in the classifier
was to transform the recorded signal using the continuous wavelet
transform (CWT). (C) Then a sliding variance was computed for each
wavelet scale. All the variances were summed across all scales resulting in
a single variance profile over time (50 ms smoothing was applied to the
resulting signal). SWD candidates were detected as threshold crossings
[red line in (C)]. Each marked segment was tested for periodic spiking
activity by detecting local maxima [red dots in (C)]. Only the detected
segments that contained at least 50% of inter-spike intervals in the range
of 2–10 Hz were included in further analysis.
inter-spike intervals for each pair of sequential maxima were
computed. Only those marked segments that contained at
least 50% of inter-spike intervals in the range of 2–10 Hz
(the typical range of SWDs) were considered as spike-wave
segments.
(7) The process was repeated several times with different para-
meters and the classified event segments were compared with
manually marked events to tune the classifier.
ANALYSIS OF SPIKE-WAVE EVENT FEATURES
Only manually marked segments were included in this analysis
to avoid distortion by borderline spike-wave-like events that were
detected by the automatic algorithm but did not necessarily share
all the features such as clear spike and wave components. The sub-
jectively selected events were identified on the basis of the classic
spike-wave morphology, by an observer blind to the origin of the
EEG. Thus the manual selection of spike-wave events resulted in a
dataset of events with a bias to less specificity and more selectivity.
The manually marked events were first low-pass filtered with a
cut-off frequency of 100 Hz. The filter removed the high frequency
components that could cause errors in feature extraction. Local
maxima were then detected in the signal and for each maximum,
its preceding and following local minima were found. The spike
components of the events were then defined as local maxima,
surrounded by local minima with a maxima–minima amplitude
of at least 400µV and with a spike width (defined below) of at
least 50 ms. Spike sequences (for computing the inter-spike time)
were defined as continuous spikes with a frequency between 5 and
13 Hz. The feature analysis was repeated several times to optimize
the parameters for the component detection.
The following features were computed for both NVHL and
control rats (Figure 3):
(1) Spike duration: the duration of the spike measured at the level
of either the preceding or the following local minimum with
the higher voltage.
(2) Spike-to-valley voltage: the voltage between the spike peak
and the following local minimum (valley).
(3) Inter-spike time: the time between two successive spikes.
(4) Wave duration: the duration of the wave component mea-
sured from the local minimum (valley) following the spike
component and the local minimum preceding the next spike
component.
(5) Wave energy: the energy of the wave component computed as
the sum of squares of amplitudes.
(6) Spike-wave event prevalence: only the automatically classified
segments were included in this analysis. Prevalence was esti-
mated as the total time spike-wave events were detected and
divided by the total amount of time that was analyzed.
STATISTICAL ANALYSIS
Group differences were compared by ANOVA or Student’s t -test.
The PLV between groups and across frequency bands were com-
pared by two-way ANOVA. Repeated-measures were not used
because the data were independently and differentially filtered for
computing the synchrony estimates at each frequency band. Sig-
nificance was set at p< 0.05, and Tukey’s HSD post hoc tests were
used as appropriate. The two-sample Kolmogorov–Smirnov test
was used to compare the probability distributions of spike-wave
event features in the NVHL and control groups. The distributions
were generated by selecting a constant subsample of spike-wave
events from each animal such that each subject contributed equally
to the distribution. The resulting distribution was then divided by
its sum to generate probability distributions that are normalized
against different numbers of subjects in the NVHL and control
groups.
RESULTS
ABNORMAL SPIKE-WAVE ACTIVITIES IN THE EEG OF NVHL RATS
Before focusing on the main aim of this study, to investi-
gate cognition-related inter-hippocampal phase synchrony during
active place avoidance cognitive behavior, we began by monitor-
ing the field potential recordings from NVHL and control rats
as they behaved in their home-cage. In the home-cage, both
groups of rats were still or moving <0.5 cm/s about 80% of the
time based on estimates from concurrent video tracking. The
most conspicuous feature was the occasional presence of a large
amplitude series of spike-wave events. We were surprised to find
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FIGURE 3 | Abnormal features of the spike-wave activities in NVHL rats.
(A) Three spike-wave cycles are shown to illustrate the features that were
measured. The analyzed features include spike duration, inter-spike time,
wave duration, spike-to-valley voltage, and inter-spike time. Comparison of the
spike-wave complex features in NVHL and control rats: (B) inter-spike time,
(C) spike duration, (D) wave duration, (E) spike-to-valley voltage, and (F) wave
energy. Distributions in each feature looked distinct, except in spike duration,
and this was confirmed statistically by the two-sample Kolmogorov–Smirnov
test in which the null hypothesis that the control and NVHL distributions were
drawn from the same underlying distribution was rejected (p<0.05).
these events and will call them spike-wave activity. They typi-
cally occurred in trains of ~6 Hz (Figure 2A). These events have
been observed in the cortical EEG of normal Long-Evans rats dur-
ing stillness and are a sign of heightened synchrony of cortical
neural activity, perhaps the rat analog of the human alpha-like
mu rhythm (32, 34). We automatically detected the individual
events and confirmed by visual inspection that the algorithm
properly detected the events (Figures 2B,C). Recordings from the
epidural cortical screw electrodes were used for analysis because
signals from the epidural cortical electrodes showed the strongest
spike-wave waveforms across all animals. We analyzed a total of
nine NVHL and seven control rats during home-cage behavior
to estimate the prevalence of the spike-wave activity. Each rat
was recorded for 3–5 h in the home-cage. The spike-wave activity
was detected in six of nine NVHL rats and three of seven con-
trol rats. The prevalence was 3% across all the NVHL rats and
2% in all the control rats. In total, 1514 spike-wave events were
detected in NVHL rats and 397 spike-wave events were detected
in control rats, suggesting that these events were more common in
NVHL rats.
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FIGURE 4 | Ethosuximide reduced the prevalence of abnormal
spike-wave activities in NVHL rats. (A) Raw EEG traces.
Ethosuximide reduced the occurrence of spike-wave activity while
olanzapine did not. (B) Quantification of the spike-wave activity
prevalence before and after drug treatment. There was an eightfold
reduction of the prevalence after ethosuximide treatment, while only a
twofold attenuation of the prevalence after olanzapine treatment in
NVHL rats (t 4 =3.79, p=0.02).
We then measured various features of the spike-wave events in
both NVHL and control rats (Figures 3A–F). The distributions
of NVHL and control groups looked distinct in all the features
except in spike duration. These were confirmed statistically by the
two-sample Kolmogorov–Smirnov test because the null hypoth-
esis that the control and NVHL distributions are drawn from
the same underlying distribution was rejected (p< 0.05) for all
features. These events tended to be larger amplitude and more
frequent in NVHL rats in comparison to the control rats. Since
we have previously characterized a cognition-related abnormal-
ity in neural synchrony in NVHL rats, in the framework of the
discoordination hypothesis, these observations of abnormal syn-
chrony suggested to us that reducing the spike-wave activities
could improve cognition and related neural activity in NVHL rats.
ETHOSUXIMIDE REDUCED THE PREVALENCE OF ABNORMAL
SPIKE-WAVE ACTIVITIES
We then evaluated whether the spike-wave activities could be
attenuated by ethosuximide, an anticonvulsant that is an antag-
onist of T-type calcium channels (35). It is used mainly to treat
absence seizures. Given the framework that animal models are best
utilized to test hypotheses about schizophrenia and that it is unwise
to assume that models themselves mimic the disease (36), we
reasoned that since ethosuximide is effective at suppressing epilep-
tiform SWDs, then it may be also be effective on the spike-wave
activities in the NVHL rats. Since it might suppress this specific
form of abnormal neural synchrony by rebalancing excitation and
inhibition, it occurred to us that ethosuximide could also act to
reduce the cognition-related abnormal neural synchrony, which
according to the discoordination hypothesis would attenuate the
cognitive deficit observed in these rats.
For comparison, we also chose to study the effects of olan-
zapine, a compound with antagonist actions at dopaminergic,
muscarinic, adrenergic, GABAergic, and histaminergic receptors.
It is one of the most widely used second-generation antipsychotic
drugs. These drugs were designed to suppress hyperlocomotion in
animal models and are prescribed to reduce the positive symptoms
of psychosis, but are not considered to be effective on cognitive
symptoms.
We observed that ethosuximide reduced the spike-wave activity
much more than olanzapine (Figure 4A). There was an eightfold
reduction in the prevalence of spike-wave activity after ethosux-
imide (100 mg/kg i.p.) treatment, while only a twofold reduction
in spike-wave activity in the NVHL rats (Figure 4B) after a dose
of olanzapine (1 mg/kg i.p.) that is sufficient to attenuate sen-
sorimotor deficits such as hyperlocomotion in the NVHL (see
Figure 7C below) and acute PCP animal models (37). These obser-
vations motivated us to test whether ethosuximide can attenuate
the abnormal cognition-related neural synchrony that we have
previously characterized in NVHL rats (12).
ETHOSUXIMIDE ATTENUATED ABNORMAL INTER-HIPPOCAMPAL
SYNCHRONY
We then turned to the main effort of this research. We recorded
LFPs while the rats performed the two-frame active place
avoidance task. We previously identified that oscillations in the
theta and beta ranges was less synchronized between the left and
right dorsal hippocampi in NVHL rats than in control rats and
that this inter-hippocampal synchrony was correlated with effec-
tive place avoidance behavior (12). Inter-hippocampal theta and
beta synchrony was weaker in the NVHL rats compared to the
controls (Figure 5A), which was already shown in prior work
(12). We administered ethosuximide and olanzapine just prior
to the first place avoidance training trials in new NVHL and
control groups. The difference in inter-hippocampal synchrony
between the NVHL and control rats was attenuated by ethosux-
imide (Figure 5B), suggesting that ethosuximide normalized inter-
hippocampal synchrony in NVHL rats. Following olanzapine,
inter-hippocampal synchrony was different between the NVHL
and control groups (Figure 5C). However, this difference appeared
because the drug increased synchrony in the NVHL rats and
decreased synchrony in the control group, especially in the theta
and beta bands. Indeed, after olanzapine, synchrony in the NVHL
rats was greater than in the treated control rats. Olanzapine also
increased inter-hippocampal synchrony in the faster frequency
gamma bands. This increase was in excess of the synchrony seen in
untreated control rats, which in contrast to ethosuximide, is why
olanzapine did not restore normal synchrony.
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FIGURE 5 | Ethosuximide attenuated abnormal cognitive
control-associated inter-hippocampal synchrony. (A) Adult NVHL
rats had lower inter-hippocampal synchrony compared to control rats
(two-way ANOVA group: F 1,32 =8.87, p=0.006; frequency:
F 3,32 =23.6, p< 0.0001; interaction: F 3,32 =7.68, p=0.0005).
Inter-hippocampal theta (t 8 =3.98, p=0.004) and beta (t 8 =2.30,
p=0.05) synchrony was weaker in the NVHL rats compared to the
controls. (B) Ethosuximide treatment attenuated the
inter-hippocampal synchrony difference between the NVHL and
control rats (two-way ANOVA group: F 1,32 =3.05, p=0.09;
frequency: F 3,32 =1.42, p=0.25; interaction: F 3,32 =0.10, p=0.96).
There was no theta (t 8 =0.73, p=0.49) or beta (t 8 = 0.94, p=0.37)
synchrony difference. (C) Olanzapine treatment increased synchrony
in NVHL rats and decreased synchrony in control rats, resulting in an
inter-hippocampal synchrony difference between the groups
(two-way ANOVA group: F 1,28 = 28.2, p<0.0001; frequency:
F 3,28 =6.20, p=0.002; interaction: F 3,28 =1.53, p=0.23).
Inter-hippocampal theta (t 7 =2.94, p=0.02) and beta (t 7 =4.43,
p=0.003) synchrony was higher in the NVHL rats compared to the
controls.
We also examined inter-hemispheric synchrony between elec-
trodes in the mPFC (Figure 6A). The synchrony of LFP oscil-
lations between the left and right-mPFC was greater for slower
frequencies than faster frequencies but not different between the
NVHL and control groups. After ethosuximide, the frequency
dependence on the magnitude of synchrony between the left and
right-mPFC was no longer observed. This was in large part because
ethosuximide increased synchrony at the faster gamma frequen-
cies, almost to the level of the slower beta frequencies. This effect
was more pronounced in the NVHL animals. Olanzapine had a
similar effect on synchrony between the left and right-mPFC sites
such that there was no longer a detectable difference in the magni-
tude of synchrony in the different frequency bands and the NVHL
and control groups were also indistinguishable.
Finally, we examined synchrony between the mPFC and dor-
sal hippocampus of one hemisphere (Figure 6B). Synchrony
was generally less than it was between the two hippocampi
or between the two mPFC. There was greater synchrony in
slower frequency bands than the faster gamma bands. There
was, however, no difference between NVHL and control ani-
mals. After ethosuximide, synchrony increased, especially in the
faster bands, for both the NVHL and control animals. This
removed the effect that synchrony was greater at slow frequencies.
The NVHL and control groups were also indistinguishable after
ethosuximide. Olanzapine increased synchrony in both NVHL
and control rats but the increase was greater for the NVHL
rats. Synchrony increased in all bands so there was no effect of
the frequency band. Clearly, both ethosuximide and olanzapine
altered the synchrony of oscillations in the LFPs of control and
NVHL rats.
ETHOSUXIMIDE ATTENUATED THE COGNITIVE CONTROL IMPAIRMENT
OF NVHL RATS
We examined whether these changes in synchrony were associ-
ated with changes in behavior using the active place avoidance
task variant that allows evaluation of the ability to use relevant
information and ignore irrelevant information, what is known
as cognitive control. We first examined the effects of the drugs
on locomotor hyperactivity (Figure 7A), which is a feature of
NVHL rats that we have previously observed during the place
avoidance task (12). Indeed, hyperactivity has been widely used to
model the positive symptoms of schizophrenia and the effect of
olanzapine in reducing hyperactivity has been shown in a variety
of schizophrenia-related animal models (38, 39). Ethosuximide
significantly reduced hyperactivity in NVHL rats compared to
control rats (Figure 7B). As expected, olanzapine also reduced
hyperactivity in NVHL rats compared to controls rats, so that the
two groups were indistinguishable (Figure 7C).
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FIGURE 6 | Inter-mPFC or inter-hippocampus-mPFC phase synchrony
was not different in the NVHL and control groups during active place
avoidance. (A) Inter-mPFC synchrony was frequency-dependent but not
different between the NVHL and control rats in the untreated groups
(two-way ANOVA group: F 1,32 =0.92, p=0.34; frequency: F 3,32 =8.97,
p=0.0001; interaction: F 3,32 =0.33, p=0.81). The inter-mPFC synchrony was
greater in the NVHL rats in the ethosuximide-treated group and the frequency
dependence was lost due to increased synchrony at the gamma frequencies
(middle: two-way ANOVA group: F 1,32 =5.42, p=0.03; frequency: F 3,32 =1.41,
p=0.26; interaction: F 3,32 = 0.16, p=0.92). In the olanzapine-treated rats, the
group and frequency dependencies were no longer observed because the
drug increased synchrony at all frequencies we assessed (right: two-way
ANOVA group: F 1,28 =1.43, p=0.24; frequency: F 3,28 =0.40, p=0.76;
interaction: F 3,28 =0.11, p=0.95) groups. (B) Inter-area synchrony (between
mPFC and hippocampus) was frequency-dependent but not different between
the NVHL and control rats in the untreated group (left: two-way ANOVA
group: F 1,32 =0.43, p=0.51; frequency: F 3,32 =5.29, p=0.005; interaction:
F 3,32 =2.05, p=0.13). There were no group or frequency dependencies in the
ethosuximide-treated rats because the drug increased synchrony at all
frequencies to the level of the maximal (theta) inter-hippocampal synchrony
(middle: two-way ANOVA group: F 1,32 =0.11, p= 0.74; frequency: F 3,32 = 0.30,
p=0.83; interaction: F 3,32 =0.07, p=0.97). The olanzapine-treated NVHL rats
had greater synchrony at all frequencies and there was no frequency
dependence because the drug also increased synchrony at all frequencies
(right: two-way ANOVA group: F 1,28 =1.22, p=0.28; frequency: F 3,28 =0.26,
p=0.85; interaction: F 3,28 =0.19, p=0.90) groups.
We then examined the effects on cognitive behavior. NVHL
rats were slower to learn the place avoidance (Figure 8A), as we
have previously reported (12). Ethosuximide attenuated the deficit
because under ethosuximide NVHL rats performed at a level that
was statistically indistinguishable from control rats, although there
was a trend for them to be slower to learn in the initial tri-
als (Figure 8B). The olanzapine treatment did not improve the
cognitive performance of NVHL rats, which remained impaired
compared to control rats (Figure 8C). In fact, olanzapine seemed
to slightly impair avoidance of the control rats during the ini-
tial trials. This was confirmed by comparing the three groups
of control rats from Figure 7 by two-way ANOVA (treatment:
F 2,96= 9.70, p= 0.0001; trials: F 7,96= 33.86, p< 0.0001; interac-
tion: F 14,96= 1.24, p= 0.26; post hoc tests: only olanzapine-treated
control rats differed from ethosuximide-treated and untreated
control rats).
Next we investigated the relationship between place avoidance
performance and inter-hippocampal synchrony in the theta and
beta bands. In the untreated NVHL and control rats, greater phase-
locking at theta and beta frequencies was significantly correlated
(r ’s> 0.8; p’s< 0.01) with better place avoidance measured as
lower total entrances (Figure 9A) but not with hyperactivity, mea-
sured as running speed (Figure 9B). The relationship between
higher synchrony and lower entrances was apparent but not
significant in the ethosuximide-treated animals (theta: r = 0.37;
p> 0.1; beta: r = 0.14; p> 0.1). Because performance was good
in most of these rats, there was limited variability in behavior for
the synchrony measures to explain. The trend of a relationship
between synchrony and cognition was reversed in the olanzapine-
treated rats. Greater synchrony was associated with worse perfor-
mance, but this trend was not significant (theta: r = 0.50; p> 0.1;
beta: r = 0.35; p> 0.1).
Finally, in the effort to describe neural coordination during
the place avoidance task, we examined the full set of 32 syn-
chrony measures (8 electrode pairs× 4 frequency bands) as a
pattern to investigate if there were group specific patterns of syn-
chrony (Figure 10). The 32-dimensional space defined by the
synchrony vectors (Figure 10A) was reduced to a 3-dimensional
space to visualize the data using the first three principal com-
ponents (Figure 10B). The data formed several clusters instead
of filling the parameter space, which suggests neural activity
may preferentially occupy preferred locales of this parameter
state space. The untreated NVHL and control animals appeared
to form two clusters. The ethosuximide and olanzapine-treated
groups occupied distinct regions of the space away from the
untreated groups. To estimate how distinct the groups might be, we
computed the average distance amongst all pairs of vectors within
a treatment group. The first six principal components accounted
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FIGURE 7 | Olanzapine and ethosuximide reduced hyperactivity in
NVHL rats. (A) In the untreated group, the NVHL rats were hyperactive
compared to control rats while performing the two-frame avoidance task
(performance curve: two-way repeated-measures ANOVA group:
F 1,64 =53.34, p<0.0001; trial: F 7,64 =2.37, p=0.03; interaction: F 7,64 = 0.46,
p=0.86); inset: average speed: t 8 =2.78, p=0.02). (B) Ethosuximide
treatment reduced hyperactivity in the NVHL rats compared to untreated
NVHL rats, and showed a statistical difference when compared to control
rats (performance curve: two-way repeated-measures ANOVA group:
F 1,64 =11.68, p=0.001; trial: F 7,64 =0.86, p=0.54; interaction: F 7,64 =1.09,
p=0.38); inset: average speed: t 8 =1.5, p=0.17). (C) Olanzapine
treatment reduced hyperactivity so there was no longer a difference from
control rats (performance curve: two-way repeated-measures ANOVA
group: F 1,64 =0.36, p=0.55; trial: F 7,64 =1.37, p=0.23; interaction:
F 7,64 =0.48, p=0.85); inset: average speed: t 8 =0.30, p=0.77).
for over 90% of the variance in the data set (Figure 10C),
so we computed the pair-wise distances as the 6-D Euclidean
distance. The average distance from the untreated NVHL group
was significantly greater for each group than it was for the vec-
tors in the untreated NVHL group (Figure 10D). Similarly, the
FIGURE 8 | Ethosuximide attenuated the cognitive control impairment
of NVHL rats. (A) In the untreated group, the NVHL rats were slower to
learn the two-frame task and showed an impairment when compared to
the control rats (learning curve: two-way repeated-measures ANOVA group:
F 1,64 =53.84, p< 0.0001; trial: F 7,64 =8.80, p<0.0001; interaction:
F 7,64 =1.79, p=0.10); inset: total number of entrances: t 8 =4.69,
p=0.002). (B) Ethosuximide treatment attenuated the learning impairment
in the NVHL rats when compared to control rats (learning curve: two-way
repeated-measures ANOVA group: F 1,64 =5.86, p=0.02; trial: F 7,64 =9.79,
p<0.0001; interaction: F 7,64 = 2.40, p=0.03); inset: total number of
entrances: t 8 =1.87, p=0.10). (C) Olanzapine treatment did not improve
performance of the NVHL rats on the two-frame task (learning curve:
two-way repeated-measures ANOVA group: F 1,64 =42.87, p<0.0001; trial:
F 7,64 =9.66, p<0.0001; interaction: F 7,64 =0.19, p=0.99); inset: total
number of entrances: t 8 =3.10, p=0.02).
distances from the untreated control vectors were significantly
greater for all other groups except the control group treated with
ethosuximide, suggesting that ethosuximide did not significantly
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FIGURE 9 | Inter-hippocampal synchrony is correlated with place
avoidance performance. (A) In the untreated NVHL and control rats, the
scatter plot distributions of theta phase-locking values (left) and beta
phase-locking values (right) show significant correlation with the total number
of errors in the two-frame avoidance task. (B) In the untreated NVHL and
control rats, theta phase-locking values (left) and beta phase-locking values
(right) were not correlated with hyperactivity, measured as running speed
during the two-frame avoidance task.
change control synchrony patterns. Because place avoidance
behavior in the NVHL group was improved by ethosuximide, we
estimated the distance between this group and the others. The
distance to the untreated control group was no different than
the distance within the NVHL-ethosuximide group, suggesting
that the two groups were relatively similar. The complementary
estimate of distance, this time to the olanzapine–NVHL group
had a different answer. All groups had greater distances to the
olanzapine–NVHL group than the distances amongst the group
itself, consistent with the synchrony pattern caused by olanzapine
being unique, rather than normalizing.
DISCUSSION
SUMMARY
The main finding of this study is that a drug that normalizes aber-
rant cognition-related neural synchrony in NVHL rats can also
attenuate the cognitive control impairment in this schizophrenia-
related neurodevelopmental model of mental dysfunction. This
work demonstrates that the pattern of abnormal cognition-related
neural synchrony is acutely normalized by ethosuximide, and fur-
thermore shows that the synchrony alterations were associated
with improved cognitive performance after ethosuximide but not
olanzapine, despite both drugs being effective at reducing hyper-
active locomotion in the NVHL model. Although olanzapine
increased theta and beta synchrony between the two hippocampi,
which is correlated with task performance (Figure 8), the drug
also increased gamma synchrony beyond baseline levels, which
may itself be associated with poor place avoidance performance
in mutant mice (40, 41). Note that under ethosuximide, and also
under olanzapine, the overall neural synchrony pattern in NVHL
rats was distinct from the untreated control pattern, but the pat-
tern after ethosuximide was closer to the control pattern than the
pattern after olanzapine (Figure 10D) and perhaps this is one of
the reasons that place avoidance performance was improved by
ethosuximide but not olanzapine.
We have used the NVHL model to examine abnormal syn-
chrony and cognitive impairment. Although NVHL rats are not a
model of schizophrenia per se, these animals are an experimental
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FIGURE 10 | Analysis of the multidimensional pattern of synchrony.
(A) Thirty-two PLV measures were extracted from the data (8 electrode
pairs×4 frequency bands) and treated as a set of 32-dimensional vectors.
PCA analysis was performed on the resulting vector dataset. The first 10
principal components (PC) are shown here (x -axis) with the relative
contribution of each measurement (y -axis) indicated by a color code. The PCs
tend to group measures with similar properties. As an example, PC #1
corresponds mostly to frequency band-non-specific phase synchrony
between the contralateral cortical electrode pairs as well as ipsilateral cortical
electrode pairs, which are measures of global cortical phase synchrony. PC #3
corresponds mostly to frequency band-non-specific phase synchrony
between the left and right-hippocampi as well as between the left and right
prefrontal cortex, which is an estimate of region-specific inter-hemispheric
synchrony. PC #6 corresponds to frequency-specific synchrony in the beta,
slow gamma, and fast gamma bands between inter-hemispheric neocortical
and hippocampal sites. The key measures of synchrony that contributed to
each PC are indicated by the dashed boxes. (B) The multidimensional data can
be visualized by plotting in the 3-D space of the first three PCs. (C) The
cumulative probability of the dataset variance is explained by the PCs. The
first six principal components explain ~90% of the dataset variance. (D) The
average Euclidean distance between a pair of vectors estimates their
distinctiveness. The distances between all pairs of vectors were computed
within a treatment group and between all treatment groups and a specific
treatment group to estimate similarity/distinctiveness of the treatment
groups. The average distances are given to the untreated NVHL group (top
row), to the untreated control group (second row), to the
ethosuximide-treated NVHL group (third row), and to the olanzapine-treated
NVHL group (bottom row).

























































Lee et al. Procognitive targeting of neural discoordination
model with neural synchrony and related cognitive abnormalities,
which allows a prediction of the discoordination hypothesis to be
tested. This unifying hypothesis was proposed to account for the
schizophrenia syndrome independent of etiology (1, 2, 12, 27, 28).
This view acknowledges that schizophrenia may turn out to be het-
erogeneous and that multiple factors contribute, including genetic
alterations, infectious, toxic, and stressful events (42,43). Whatever
the etiology, the discoordination hypothesis asserts that disruption
of the physiological synchronization of neural activities produces
cognitive abnormalities in schizophrenia, despite otherwise seem-
ingly normal expression of unitary physiological phenomena. The
hypothesis is based specifically on the physiological coordination
of neural activities, defined as the set of neural processes that
control the timing of spike discharge across ensembles of neu-
rons (1, 29, 44, 45). Our group has demonstrated this neural
coordination during cognitive control in active place avoidance
tasks (46, 47). The current findings support the discoordina-
tion hypothesis by demonstrating that correcting the neural syn-
chrony abnormality in NVHL rats can be associated with cognitive
improvement, which was the case with ethosuximide but not with
olanzapine. Olanzapine did not normalize either neural synchrony
or cognitive behavior (Figures 4, 5, and 8). In further support of
the hypothesis, olanzapine caused abnormal neural synchrony in
control rats, which seemed to worsen the place avoidance.
SPIKE-WAVE ACTIVITY
A secondary finding in this study is that spike-wave like activity
was observed in the epidural cortical EEG of both NVHL and con-
trol rats during stillness in the home-cage and only rarely during
active place avoidance behavior, consistent with prior observations
(32, 34). This observation may have implications for how deficits
in NVHL animals are interpreted when those deficits are char-
acterized in tasks during which there is behavioral stillness, like
pre-pulse inhibition, inhibitory avoidance, and food-motivated
radial-arm mazes. Complex interactions of inhibitory and excita-
tory systems between the thalamus and cortical structures generate
a variety of normal and abnormal rhythmic states including spin-
dle waves and SWDs during absence seizures. Spindle waves are
characterized by 1–4 s periods of 6–14 Hz oscillations during nor-
mal sleep (48). The characteristic frequency of the SWD is 3–4 Hz
in humans (49) and is normally higher (4–12 Hz) in rodents
(50, 51). Our analysis of cortical spike-wave activity shows that
the features of the spike-wave activity in NVHL and control rats
are different (Figure 2). The duration of the activity was greater
in NVHL rats compared to control rats, further suggesting that
this activity in the NVHL rats may be of a different neural origin
than it is in control rats. In NVHL rats it may reflect a form of
pathological network synchrony and even a sign of epileptiform
propensity (52).
Indeed, during several hours of continuous monitoring, we
have observed rare, but nonetheless bona fide epileptiform dis-
charges and behavioral seizures in NVHL rats (52). The NHVL
rats may have increased susceptibility to seizures due to dysregula-
tion of the GABA system (53, 54). There is widespread reduction
of GAD67 expression (54, 55), and decreased expression of PV
interneurons in the prefrontal cortex and the hippocampus (54)
in these rats. There is also increased firing in pyramidal neurons
in the NVHL rats. The mPFC pyramidal neurons of NVHL rats
respond to stimulation of the ventral tegmental area, the ori-
gin of dopamine projections to the PFC, with an increase in
firing rates (56) instead of the normal decrease (57), indicating
hyperexcitability. It has been shown that NVHL rats developed
epileptiform SWDs at a twofold lower dose of pentylenetetra-
zol (PTZ, a GABAA antagonist) than sham-operated rats, fur-
ther evidence that the NVHL rats have increased susceptibility
to absence-like seizures (54). Indeed, PD7 injections into ventral
hippocampus with kainate, an excitotoxin with a different mecha-
nism of action than ibotenate (58), is used as a model of temporal
lobe epilepsy (59). Perturbations of the GABA system, together
with the aberrant response reflecting the inability of dopamine to
activate interneurons, may result in enhanced cortical excitability
and abnormal spike-wave activity in NVHL rats.
ETHOSUXIMIDE TREATMENT
We now discuss the effects of ethosuximide in the contexts of its
pharmacological actions, typical use as well as the relevance of
the findings with ethosuximide to understanding the cognitive
impairments in the NVHL rat model and mental illness such as
schizophrenia. To be clear, neither the findings nor the discussion
that follows suggest that ethosuximide might be an effective treat-
ment for schizophrenia. Rather, the procognitive and normalizing
neural coordination effects of ethosuximide in the NVHL model
provides new evidence that attenuating neural synchrony deficits
can itself be procognitive.
Ethosuximide is used extensively to treat absence (petit mal)
seizures (60–62). The mechanism of action is to block low-
threshold Ca2+ currents in the T-type Ca2+ channels and enhance
GABAergic tone (63, 64). We observed that ethosuximide reduced
spike-wave activity in NVHL rats, indicating it is effective on
abnormal synchrony in NVHL rats during home-cage behav-
iors (Figure 3). The drug also increased inter-hippocampal syn-
chrony in NVHL rats so that neural coordination between the
two hippocampi approached normal levels in the theta- and beta-
frequency bands. Nonetheless, taken together, after ethosuximide,
the overall pattern of neural synchrony in the NVHL rats was mod-
ified but the pattern of synchronies was not restored to the pattern
of the untreated controls. Indeed, ethosuximide also changed the
synchrony pattern in the controls animals too, but these changes
were not associated with cognitive disability.
The effectiveness of ethosuximide may be contemplated in rela-
tion to the fact that the synchronization of oscillations reflects the
temporally precise interaction of neural activities (65). Such coor-
dinated interactions result from an appropriate balance between
GABA-mediated inhibition and glutamate-mediated excitation,
which may be unbalanced in adult NVHL rats (56). Alterations
in one or both of these systems can result in abnormal network
synchrony. Schizophrenia has been associated with dysregulation
of cortical GABAergic neurotransmission (66) and abnormali-
ties in NMDA-receptor mediated neurotransmission (67). There
are significantly decreased levels of GABAergic neuronal mark-
ers like parvalbumin mRNA in the prefrontal cortex (68, 69) and
in the dorsolateral prefrontal cortex of schizophrenia patients,
decreased levels have been reported of glutamic acid decarboxylase
(GAD67) mRNA, the GABA-synthesizing enzyme (70,71). Indeed,
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NMDA-receptor hypofunction in schizophrenia (72, 73) is now
thought to primarily affect GABA inhibition by reducing GABAer-
gic tone. Thus dysregulation of excitatory and inhibitory neuro-
transmission contribute to abnormalities in the coordination of
neural activities, which according to the hypothesis, is the basis for
the impaired cognitive functions that are central to schizophrenia
and a logical target for developing cognition promoting therapies.
It was recently proposed that aberrant low frequency delta/theta
oscillations emerge as a consequence of NMDA-receptor hypo-
function (3, 74). The reduced excitation would deinactivate T-type
Ca2+ channels and exaggerate bursting, especially in thalamic neu-
rons, which may be the origin of the low frequency thalamocortical
oscillations that could disrupt cortical function in schizophrenia
(75). In this context, given ethosuximide’s mechanism of action,
it is perhaps not surprising that the drug both normalized neural
synchrony and improved cognition in NVHL rats. Ethosuximide
reduces excitability primarily by blocking activity-dependent low-
threshold Ca2+ currents as well as by acting as a partial agonist at
the picrotoxin GABA-blocking receptor (64).
In the absence of the forgoing discussion, it may seem
surprising to some readers that ethosuximide can improve inter-
hippocampal synchrony and place avoidance behavior. Some read-
ers may have assumed that because ethosuximide is antiepileptic
it must decrease neural synchrony because epileptiform activity
is thought of as excessive synchrony. According to these opinions,
ethosuximide would decrease synchrony, not increase it, and thus
worsen place avoidance behavior in control as well as NVHL rats.
As we have pointed out in the Section “Introduction,” epileptiform
activity is not simply excessive synchrony, and in the NVHL rat,
we have measured the evidence of widespread decreases of syn-
chrony between brain areas, resembling functional disconnection
(52). Embedded in this loosening of neural coordination, perhaps
by excitation–inhibition uncoupling, we also observed that some
brain areas can exhibit relatively increased synchrony. Thus, there
are alternative conceptualizations of the ethosuximide effects but
they are not supported by the data on the subject in general or on
NVHL rats in particular.
Ethosuximide treatment also reduced hyperactivity in NVHL
rats, which in animal models, is widely studied as a behavioral
analog of the positive symptoms of schizophrenia, although the
reduction was not as effective as after olanzapine. Blocking T-type
Ca2+ channels can produce antipsychotic effects in rats by atten-
uating the psychomotor effects of both the NMDA antagonist
MK-801 and amphetamine, the dopaminergic psychostimulant
(76). T-type Ca2+ channels are widely expressed in the brain,
including areas such as the thalamus, the prefrontal cortex, the
hippocampus, and the nucleus accumbens (77), which are regions
that have been reported to function abnormally in schizophrenia
(74, 78, 79). Interestingly, a number of clinically validated antipsy-
chotics, including haloperidol, pimozide, flunarizine, and clozap-
ine, are potent T-type channel antagonists (76, 80–82). A recent
genome-wide study of single-nucleotide polymorphisms (SNP)
found that variations in calcium channel genes are associated with
schizophrenia as well as a range of major psychiatric disorders
(83). These data implicate calcium channels in the pathophysiol-
ogy of schizophrenia, and while calcium channel abnormality may
help to account for why ethosuximide was effective on NVHL rats,
it is also possible that ethosuximide was effective because of its
fundamental effects on excitation–inhibition balance through the
action on otherwise normal calcium channels. Nonetheless, the
present work does not imply and we do not propose to use etho-
suximide as a treatment for cognitive deficits in schizophrenia.
Rather the present findings demonstrate that procognitive effects
may be possible if treatments can normalize the coordination of
neural activity between cognitive processing centers like the two
hippocampi.
OLANZAPINE TREATMENT
Second-generation (atypical) antipsychotic medications, includ-
ing olanzapine, are effective in treating psychosis, hallucina-
tions, and delusions (84) but ineffective in treating the cognitive
impairments that strongly debilitate schizophrenia patients (85).
Olanzapine, a thienobenzodiazepine derivative, is classified as a
multi-acting receptor-targeted antipsychotic, showing high affin-
ity for dopaminergic, serotonergic, cholinergic, histaminergic, and
muscarinic receptors (86, 87). As expected, we observed that olan-
zapine reduced hyperactivity in NVHL rats to control levels during
the place avoidance task, indicating we used an effective antipsy-
chotic dose, at least by traditional measures. The dose was however,
ineffective at improving cognitive performance of NVHL rats in
the two-frame task. This is of course consistent with the drug’s
lack of effect on cognitive symptoms in patients.
Olanzapine treatment in NVHL and control rats showed a
reversed effect on neural synchrony. Olanzapine increased inter-
hippocampal synchrony in NVHL rats to the level of untreated
controls in the theta and beta bands and in excess of the con-
trol levels in the gamma bands. In contrast, the drug decreased
inter-hippocampal synchrony in control rats. The increased syn-
chrony in olanzapine-treated NVHL rats was not associated with
improved cognitive performance in the NVHL rats, which would
be at odds with the discoordination hypothesis, except that after
olanzapine, the gamma synchrony was excessive, indicating that
olanzapine changed neural coordination, but as demonstrated
with the multidimensional synchrony analysis (Figure 10), the
synchrony changes did not normalize neural synchrony in NVHL
rats. Conversely, but also in support of the discoordination
hypothesis, the decreased synchrony in olanzapine-treated con-
trol rats was associated with a higher number of errors in the
two-frame task when compared to untreated control rats, which is
consistent with the observation that the drug changed the neural
synchrony pattern in control animals to a pattern that is substan-
tially distinct (Figures 10B,D) from the untreated control pattern.
It is well documented that antipsychotic drugs cause EEG abnor-
malities associated with general slowing of background activity, an
increase in paroxysmal theta or delta activity and the development
of epileptiform discharges (88). In patients on olanzapine, there
is an increased diffuse and intermittent slowing of the EEG (89,
90) and an increased high risk of EEG abnormalities such as theta
and delta slowing, sharp waves or phase reversal, and/or spike-
wave activities (88, 91). Healthy subjects on olanzapine showed an
increased power in the theta band and a decrease in the beta band
(92). In summary, olanzapine normalized inter-hippocampal syn-
chrony in the theta and beta bands but it also caused abnormal syn-
chrony changes in both the NVHL and control rats that were not
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associated with improved cognitive performance in the two-frame
task.
CONCLUSION
The findings reported here are consistent with the main assertion
and prediction of the discoordination hypothesis that abnor-
mal neural synchrony during cognitive effort is associated with
impaired cognition and that restoring normal synchrony will pro-
mote cognition. As shown here, targeting the pathophysiology of
abnormal neural coordination, regardless of the etiology, may be
both a rational and effective program for developing a much-
needed generation of procognitive treatments for mental illness in
general and schizophrenia in particular.
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